New eBook Explores the Changing Landscape of Canine Cancer – Featuring Vetigenics
A Practical Guide to Prevent, Detect, and Manage Canine Cancer is a new eBook produced in partnership with INNOVATION News Network.
How Pet Dogs Are Helping to Advance Lymphoma Breakthroughs
Back in 2018, nine pet dogs suffering from various types of cancer participated in the clinical trial of an immunotherapy treatment that was developed by engineering a livestock virus called vesicular stomatitis virus.
Vetigenics: Bridging biotechnology and veterinary care for a healthier future
Vetigenics is transforming the treatment of challenging diseases in pets with innovative technology that generates best-in-class antibody therapies.
Vetigenics secures $6 million seed financing, sees meaningful clinical progress
Pet biotech establishes board of directors, looks ahead to therapies for autoimmune disease, obesity and allergy.
Looking back, looking forward: Penn’s CAR-T program continues path of progress
In 2018, at the height of the chimeric antigen receptor T-cell therapy revolution and in the heart of its implementation, Healio’s Cell Therapy Next staff went onsite to University of Pennsylvania’s newly minted center.
Could pharma’s blockbuster immunotherapies work in dogs?
Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals. Read More
First canine patient receives Vetigenics’ fully canine anti-CTLA4 monoclonal antibody for oral melanoma
Two fully funded pilot studies to treat cancer free for pet owners who bring their dogs to research sites. PHILADELPHIA, Nov. 2, 2023—Vetigenics, a clinical-stage biopharmaceutical company advancing antibody-based therapies for pets, announces that the first canine patient with stage 4 oral melanoma has received his first dose of Vetigenics’ fully canine anti-CTLA4 monoclonal antibody […]
Vetigenics’ Canibody platform attracting more potential collaborators
US pet therapeutics start-up Vetigenics is seeing increased interest from potential collaborators in its Canibody. Adriann Sax, the co-founder and chief executive of the Philadelphia-based company, recently revealed the company’s progress to S&P Global’s head of animal health Joseph Harvey. In late 2022, Vetigenics secured its second discovery partner for its companion animal therapeutic antibody […]
Enhancing Canine Wellness: The Promise of Immunotherapy for Dogs
Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight health issues, such as […]
Vetigenics Announces Second Discovery Collaboration with a Major Animal Health Pharma
New partnership established to explore multiple novel therapeutic antibodies for treating challenging pet diseases. Read More